The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function
Open accessAbstract
Recent advances in pluripotent stem cell research have provided investigators with potent sources of cardiogenic cells. However, tissue engineering methodologies to assemble cardiac progenitors into aligned, 3-dimensional (3D) myocardial tissues capable of physiologically relevant electrical conduction and force generation are lacking. In this study, we introduced 3D cell alignment cues in a fibrin-based hydrogel matrix to engineer highly functional cardiac tissues from genetically purified mouse embryonic stem cell derived cardiomyocytes (CMs) and cardiovascular progenitors (CVPs). Procedures for CM and CVP derivation, purification, and functional differentiation in monolayer cultures were first optimized to yield robust intercellular coupling and maximize velocity of action potential propagation. A versatile soft-lithography technique was then applied to reproducibly fabricate engineered cardiac tissues with controllable size and 3D architecture. While purified CMs assembled into a functional 3D syncytium only when supplemented with supporting non-myocytes, purified CVPs differentiated into cardiomyocytes, smooth muscle, and endothelial cells, and autonomously supported the formation of functional cardiac tissues. After a total culture time similar to period of mouse embryonic development (21 days), the engineered cardiac tissues exhibited unprecedented levels of 3D organization and functional differentiation characteristic of native neonatal myocardium, including: 1) dense, uniformly aligned, highly differentiated and electromechanically coupled cardiomyocytes, 2) rapid action potential conduction with velocities between 22 and 25 cm/s, and 3) significant contractile forces of up to 2 mN. These results represent an important advancement in stem cell-based cardiac tissue engineering and provide the foundation for exploiting the exciting progress in pluripotent stem cell research in the future tissue engineering therapies for heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Langer, R., & Vacanti, J. P. (1993) · Science · doi:10.1126/science.8493529 · Cited by 9,893
Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart
Ott, H. C., Matthiesen, T. S., Goh, S.-K., Black, L. D., Kren, S. M., Netoff, T. I., & Taylor, D. A. (2008) · Nature Medicine · doi:10.1038/nm1684 · Cited by 2,650 · cited 2×
“Moreover, even thoughour initial cell source consistedofundifferentiatedmESCs, the obtained functional properties are comparable to thoseof engineered 2D monolayers [32,55,56] and 3D tissues [3,41,49,52] made starting from considerably more mature neonatal rat ventricular cells.”
BackgroundResultHuman cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population
Yang, L., Soonpaa, M. H., Adler, E. D., Roepke, T. K., Kattman, S. J., Kennedy, M., Henckaerts, E., Bonham, K., Abbott, G. W., Linden, R. M., et al. (2008) · Nature · doi:10.1038/nature06894 · Cited by 1,389 · cited 1×
“While this study suggests puromycin-selected Nkx2-5þ progenitors as the optimal source for cardiac tissue engineering, it is unknown if other cardiogenic cell sources, derived from pluripotent stemcells either bygenetic selection [7,63] ordirected differentiation [5,6], could yield engineered tissues with enhanced fun…”
ResultAccordion-like honeycombs for tissue engineering of cardiac anisotropy
Engelmayr, G. C., Cheng, M., Bettinger, C. J., Borenstein, J. T., Langer, R., & Freed, L. E. (2008) · Nature Materials · doi:10.1038/nmat2316 · Cited by 848
Growth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666
Tissue engineering of vascularized cardiac muscle from human embryonic stem cells
Caspi, O., Lesman, A., Basevitch, Y., Gepstein, A., Arbel, G., Habib, I. H. M., Gepstein, L., & Levenberg, S. (2007) · Circulation Research · doi:10.1161/01.res.0000257776.05673.ff · Cited by 558 · cited 2×
“The mechanisms of cardiomyocyte/non-myocyte interactions in the context of cardiac development and tissue engineering remain unknownand are likely to depend on non-myocyte type [9,10,12], age [61] andnumber [41] and involve different cell contact, paracrine, and extracellular matrix mediated effects.”
BackgroundDevelopment of a drug screening platform based on engineered heart tissue
Hansen, A., Eder, A., Bönstrup, M., Flato, M., Mewe, M., Schaaf, S., Aksehirlioglu, B., Schwörer, A., Uebeler, J., & Eschenhagen, T. (2010) · Circulation Research · doi:10.1161/circresaha.109.211458 · Cited by 510
Black, L. D., Meyers, J. D., Weinbaum, J. S., Shvelidze, Y. A., & Tranquillo, R. T. (2009) · Tissue Engineering Part A · doi:10.1089/ten.tea.2008.0502 · Cited by 161
Contractile three-dimensional bioengineered heart muscle for myocardial regeneration
Huang, Y., Khait, L., & Birla, R. K. (2007) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31090 · Cited by 90 · cited 1×
“While hydrogel scaffolds based on type I collagen have been traditionally used for cardiac tissue engineering [8, 12, 17–20], others [21–23] and us [24] have utilized fibrin-based hydrogels due to their proven biocompatibility and unique biomechanical properties.”
Cited by
Current advances and future perspectives in extrusion-based bioprinting
Ozbolat, I. T., & Hospodiuk, M. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.076 · Cited by 1,572
3D Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts
Noor, N., Shapira, A., Edri, R., Gal, I., Wertheim, L., & Dvir, T. (2019) · Advanced Science · doi:10.1002/advs.201900344 · Cited by 1,042
Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939
Zhang, D., Shadrin, I. Y., Lam, J., Xian, H.-Q., Snodgrass, H. R., & Bursac, N. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.026 · Cited by 565
Self-citationRuan, J.-L., Tulloch, N. L., Razumova, M. V., Saiget, M., Muskheli, V., Pabon, L., Reinecke, H., Regnier, M., & Murry, C. E. (2016) · Circulation · doi:10.1161/circulationaha.114.014998 · Cited by 467
Cardiac Tissue Engineering: State of the Art
Hirt, M. N., Hansen, A., & Eschenhagen, T. (2014) · Circulation Research · doi:10.1161/circresaha.114.300522 · Cited by 425
Shadrin, I. Y., Allen, B. W., Qian, Y., Jackman, C. P., Carlson, A. L., Juhas, M. E., & Bursac, N. (2017) · Nature Communications · doi:10.1038/s41467-017-01946-x · Cited by 420
Self-citationHydrogels for tissue engineering and regenerative medicine
Hunt, J. A., Chen, R., van Veen, T., & Bryan, N. (2014) · J. Mater. Chem. B · doi:10.1039/c4tb00775a · Cited by 377
Golpanian, S., Wolf, A., Hatzistergos, K. E., & Hare, J. M. (2016) · Physiological Reviews · doi:10.1152/physrev.00019.2015 · Cited by 343
Engineering human pluripotent stem cells into a functional skeletal muscle tissue
Rao, L., Qian, Y., Khodabukus, A., Ribar, T., & Bursac, N. (2018) · Nature Communications · doi:10.1038/s41467-017-02636-4 · Cited by 334
Self-citation3D bioprinted functional and contractile cardiac tissue constructs
Wang, Z., Lee, S. J., Cheng, H.-J., Yoo, J. J., & Atala, A. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.02.007 · Cited by 298
Tissue Engineering Approaches in the Design of Healthy and Pathological In Vitro Tissue Models
Caddeo, S., Boffito, M., & Sartori, S. (2017) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2017.00040 · Cited by 285
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
Juhas, M., Engelmayr, G. C., Fontanella, A. N., Palmer, G. M., & Bursac, N. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402723111 · Cited by 246
Self-citationKensah, G., Roa Lara, A., Dahlmann, J., Zweigerdt, R., Schwanke, K., Hegermann, J., Skvorc, D., Gawol, A., Azizian, A., Wagner, S., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs349 · Cited by 193
In vitro cardiac tissue models: Current status and future prospects
Mathur, A., Ma, Z., Loskill, P., Jeeawoody, S., & Healy, K. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.011 · Cited by 187
“CMs differentiated from ESCs and from cardiac progenitor cells (CPCs) were seeded into this engineered hydrogel to yield highly aligned CMs and robust intercellular coupling with rapid action potential conduction (22–25 cm/s) and significant contractile forces (up to 2 mN) [85, 86].”
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium
Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-228007 · Cited by 184
“Since nonmyocytes can substantially affect cardiac cells (6, 16, 25, 26, 28), generation of human ECTs using well-defined cell populations is critical for studying the effects of heterocellular interactions on hECT viability, maturation, and function under controlled conditions.”
BackgroundTzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162
Fibrous scaffolds for building hearts and heart parts
Capulli, A. K., MacQueen, L. A., Sheehy, S. P., & Parker, K. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.11.020 · Cited by 130
Physical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes
Zhu, R., Blazeski, A., Poon, E., Costa, K. D., Tung, L., & Boheler, K. R. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt507 · Cited by 110
Wendel, J. S., Ye, L., Tao, R., Zhang, J., Zhang, J., Kamp, T. J., & Tranquillo, R. T. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0044 · Cited by 105
Organs-on-a-chip: a union of tissue engineering and microfabrication
Zhao, Y., Wang, E. Y., Lai, F. B. L., Cheung, K., & Radisic, M. (2023) · Trends in Biotechnology · doi:10.1016/j.tibtech.2022.12.018 · Cited by 93
Keung, W., Boheler, K. R., & Li, R. A. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt406 · Cited by 87
Bioengineering approaches to treat the failing heart: from cell biology to 3D printing
Yadid, M., Oved, H., Silberman, E., & Dvir, T. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00603-7 · Cited by 83
Blazeski, A., Lowenthal, J., Zhu, R., Ewoldt, J., Boheler, K. R., & Tung, L. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.04.002 · Cited by 40
Metadata
- Authors
- Liau, B., Christoforou, N., Leong, K. W., & Bursac, N.
- Venue
- Biomaterials
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 32
- Issue
- 35
- Pages
- 9180-9187
- ISSN
- 0142-9612 (ISSN-L)
- OpenAlex
- W2104697565
- Cited by
- 233
- References
- 9
- FWCI
- 16.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.